undamentalytics Newsletter

Bvf Inc/il: insider trades

Director, 10% owner at 5 companies we cover. 7 open-market purchases and 2 sales not made under a pre-set plan, reported from October 25, 2011 to May 16, 2022.

Would copying Bvf Inc/il’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 5 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on October 26, 2011 into $15,946 by November 2, 2026, +3.2% a year. The copy held shares only 22% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $17,272, +3.7% a year (the S&P 500 held throughout made $79,027, +14.8% a year). Beta against the index was 0.33. Twelve months after each report, the average purchase was +24.3% against the S&P 500 (median −7.0%), and 40% beat it. Measured from the trade date, the insider’s own timing, the average was +33.8%. After their sales, the shares moved −19.4% against the index over 12 months on average (a negative figure means selling was the right call); 100% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$25.0k$50.0k$75.0k 20112013201520172019202120232025 $79.0k$17.3k$15.9k
Copying Bvf Inc/ilS&P 500, same days investedS&P 500, held throughout $10,000 copying Bvf Inc/il’s open-market purchases from October 26, 2011, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
+3.2%
S&P 500, same days invested
+3.7% (held throughout +14.8%)
Time in shares
22%
Sharpe ratio (S&P 500)
0.19 (0.81)
Biggest drop (S&P 500)
−67% (−34%)
Market sensitivity (beta)
0.33
Purchases copied
5

Trade by trade

Bvf Inc/il: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 5 +7.4% +3.8% 60% 3 — — Not enough years
Purchases, 6 months after the report 5 +15.3% +7.5% 60% 3 — — Not enough years
Purchases, 12 months after the report 5 +24.3% −7.0% 40% 3 — — Not enough years
Purchases, 12 months after the trade 5 +33.8% +3.5% 80% 3 — — Not enough years
Sales, 3 months after the report 1 +26.0% +26.0% 0% 1 — — Not enough years
Sales, 12 months after the report 1 −19.4% −19.4% 100% 1 — — Not enough years
Sales, 12 months after the trade 1 −24.2% −24.2% 100% 1 — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Ligand Pharmaceuticals Inc LGND —21October 25, 2011November 29, 2013
Crescent Biopharma, Inc. CBIO —20November 3, 2020November 6, 2020
Kymera Therapeutics, Inc. KYMR —20January 31, 2022May 9, 2022
Rigel Pharmaceuticals Inc RIGL —01November 20, 2013November 20, 2013
Cullinan Therapeutics, Inc. CGEM —10May 16, 2022May 16, 2022

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
May 16, 2022May 12, 2022 CGEM Purchase $10,064,486 +3.8%−31.4%+3.4%
May 9, 2022May 5, 2022 KYMR Purchase $4,866,000 +80.1%+48.7%+37.1%
January 31, 2022January 27, 2022 KYMR Purchase $5,076,291 −36.7%−7.0%+3.6%
November 6, 2020November 4, 2020 CBIO Purchase $3,293,516 not yetnot yetnot yet
November 3, 2020October 30, 2020 CBIO Purchase $2,564,683 not yetnot yetnot yet
November 29, 2013November 26, 2013 LGND Sale $30,208,960 +26.0%−19.4%−24.2%
November 20, 2013November 19, 2013 RIGL Sale $1,279,402 not yetnot yetnot yet
December 18, 2012December 14, 2012 LGND Purchase $100,341 +10.4%+120.1%+130.4%
October 25, 2011October 21, 2011 LGND Purchase $64,078 −20.7%−9.0%−5.6%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Bvf Inc/il traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.